Analyst Price Targets — NMRA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 12, 2026 10:20 am | Marc Goodman | Leerink Partners | $8.00 | $2.27 | TheFly | Neumora Therapeutics initiated with an Outperform at Leerink |
| January 5, 2026 2:51 pm | Graig Suvannavejh | Mizuho Securities | $6.00 | $1.72 | StreetInsider | Neumora Therapeutics (NMRA) PT Raised to $6 at Mizuho |
| December 1, 2025 10:35 am | — | RBC Capital | $7.00 | $2.24 | TheFly | Neumora Therapeutics upgraded to Outperform from Sector Perform at RBC Capital |
| October 28, 2025 11:50 am | — | Needham | $8.00 | $2.60 | TheFly | Neumora Therapeutics price target raised to $8 from $6 at Needham |
| March 7, 2025 9:48 am | — | Stifel Nicolaus | $2.00 | $1.49 | TheFly | Neumora Therapeutics downgraded to Hold from Buy at Stifel |
| January 2, 2025 4:06 pm | Brian Abrahams | RBC Capital | $4.00 | $1.97 | StreetInsider | RBC Capital Downgrades Neumora Therapeutics (NMRA) to Sector Perform |
| July 22, 2024 6:16 am | Ami Fadia | Needham | $23.00 | $11.28 | TheFly | Neumora Therapeutics initiated with a Buy at Needham |
| July 8, 2024 6:35 am | Graig Suvannavejh | Mizuho Securities | $20.00 | $10.25 | TheFly | Neumora Therapeutics initiated with an Outperform at Mizuho |
| June 17, 2024 6:23 am | Brian Abrahams | RBC Capital | $29.00 | $9.71 | StreetInsider | RBC Capital Reiterates Outperform Rating on Neumora Therapeutics (NMRA) |
| March 13, 2024 12:07 pm | Brian Abrahams | RBC Capital | $31.00 | $14.81 | StreetInsider | RBC Capital Out Positive on Neumora Therapeutics (NMRA): ' See Compelling Entry Point Ahead of Key 2H24 Catalysts' |
Latest News for NMRA
NMRA-511 demonstrated a clinically meaningful effect size in people with AD agitation.
Neumora Therapeutics (NASDAQ: NMRA) executives highlighted new clinical-scale analyses for NMRA-511 in Alzheimer's disease (AD) agitation and reviewed pipeline milestones during a presentation at the Guggenheim Emerging Outlook Biotech Summit 2026. NMRA-511: Additional Phase 1b analyses in AD agitation President Josh Pinto said the company shared additional data from a phase 1b "signal-seeking" study of NMRA-511
Neumora Therapeutics, Inc. (NASDAQ: NMRA - Get Free Report) has earned an average recommendation of "Hold" from the eleven research firms that are presently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell rating, two have given a hold rating, five have given a buy rating and one has
WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on…
Shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA - Get Free Report) have been given an average rating of "Hold" by the ten analysts that are presently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a sell recommendation, two have given a hold recommendation and five have given a buy recommendation to the
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NMRA.
U.S. House Trading
No House trades found for NMRA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.